publication date: Mar. 8, 2019
NCI Trials for March
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10214
Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Lipson, Evan Jacob
Phase I – 10241
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
NCI Center for Cancer Research
Phase I – 10246
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
University Health Network Princess Margaret Cancer Center LAO
Shafer, Danielle A
Phase I/II – 10195
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Duke University – Duke Cancer Institute LAO
Dees, Elizabeth Claire
Phase I/II – ABTC-1801
Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations
Adult Brain Tumor Consortium
Bindra, Ranjit S
Phase I/II – PBTC-053
A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH … Continue reading NCI Trials for March 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.